The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical benefits of bevacizumab in metastatic colorectal cancer depending on KRAS status.
Keisuke Kurimoto
No relevant relationships to disclose
Kiyoshi Ishigure
No relevant relationships to disclose
Yoshiyasu Kato
No relevant relationships to disclose
Yasuyuki Asai
No relevant relationships to disclose
Nobutake Tanaka
No relevant relationships to disclose
Song Ryo
No relevant relationships to disclose
Hidenobu Matsushita
No relevant relationships to disclose
Junichi Tobinaga
No relevant relationships to disclose
Ryuichi Fukuyama
No relevant relationships to disclose
Hiruhumi Kuroda
No relevant relationships to disclose
Tomoo Fujii
No relevant relationships to disclose